Skip to main content
OpenTrials
Completed

NCT Number: NCT05407298

The Use of Cannabidiol in Cancer Patients

Alternative and complementary medicines (MAC) are commonly used by cancer patients to help them to face with anticancer treatment, reduce oncology symptoms and/or anticancer treatment adverse effects, detoxifying the body. In consistence with guidelines from the French Society for Oncology Pharmacy (SFPO), the pharmaceutical consultation includes a discussion and collection of herbs, botanical and other natural products consumed by cancer patients. This aim to prevent and manage herb-drug interaction as well as other drug-related problems (DRP). The recent French experimentation dedicated to cannabidiol for medical use could enhance interest of cancer patients in the field of MAC. However, cannabidiol have shown inhibitory effect on different cytochromes with a risk of HDI as other MAC. While the prevalence of MAC consumption is already known in some type of cancer, the consumption of CBD is less known and should be explored. Through this study we wish to know the prevalence of cannabidiol consumption in cancer patients and to establish a typical profile as well as to know the modalities of use. We also want to validate a questionnaire through a literacy scale.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Damien JOLLY

Reims, France

About this study

  • A Prospective observational study
  • Conducted in an oncology day-hospital (CHU de Reims)

All data collected were:

  • Clinical characteristics,
  • Administrative data,
  • Medication review,
  • Biologic data collection,
  • Oncological data,
  • Disease data

Statistical analysis:

  • Quantitative variables: described as mean ± standard deviation (SD) or median (Interquartile range and minimum and maximum)
  • Student test and Fischer exact performed to compare CBD users and non-users.
  • Analysis of variance: used to compare scores between different variables
  • Univariate logistic and multivariate logistic regressions were performed. Variables with a p-value < 0.20 (Wald test) in the univariable analyses were considered eligible for the multivariable models.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All the patients (>18yo) who received anticancer treatment

Exclusion criteria

  • Patients who received anticancer drug with very short administration time (typically subcutaneous anticancer drugs as 5-azacitidine, bortezomib and some monoclonal antibodies)
  • Patients who were not able to speak and understand French as well as who were unable to communicate clearly.

Treatment and study plan

Non applicable

Other

Non Applicable

Primary outcomes

  1. Prevalence of CBD consummation among patients receiving anticancer treatment

    Time frame: Day 0

Secondary outcomes

  1. Knowledge assessment of cancer patients with the CBD medical use in the literacy scope

    Time frame: Day 0

Sponsors and collaborators

Lead sponsor

CHU de Reims

Other

Registry information

Official study title

Prevalence of Cannabidiol (CBD) Consumption and Cancer Patients' Expectations in One Oncology Day-Hospital: A Cross-sectional Study and Questionnaire Validation

Acronym: CANPADIOL

Important dates

Study start
2021
Primary completion
2021
Study completion
2022
First posted
Jun 7, 2022
Registry last updated
Jun 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.